Moomoo AI 已提取核心訊息
Conduit Pharmaceuticals Inc. has filed a registration statement on Form S-8 with the Securities and Exchange Commission (SEC) on January 10, 2024. This filing registers an additional 3,691,476 shares of common stock that may be issued under the company's 2023 Stock Incentive Plan. The plan includes an automatic annual increase in the number of shares available for issuance, which will occur on the first day of each fiscal year starting January 1, 2024, and will continue through January 2033. The increase is the lesser of 5% of the outstanding common stock at the end of the preceding fiscal year or a smaller number determined by the board of directors or its Compensation Committee. The newly registered shares are a result of this 'Plan Evergreen Provision'. Previously, up to 11,497,622 shares were registered under a prior Form S-8 filed on December 1, 2023. The contents of the prior registration statement are incorporated by reference into this new registration statement, which includes only new information not previously disclosed.
Conduit Pharmaceuticals Inc. has filed a registration statement on Form S-8 with the Securities and Exchange Commission (SEC) on January 10, 2024. This filing registers an additional 3,691,476 shares of common stock that may be issued under the company's 2023 Stock Incentive Plan. The plan includes an automatic annual increase in the number of shares available for issuance, which will occur on the first day of each fiscal year starting January 1, 2024, and will continue through January 2033. The increase is the lesser of 5% of the outstanding common stock at the end of the preceding fiscal year or a smaller number determined by the board of directors or its Compensation Committee. The newly registered shares are a result of this 'Plan Evergreen Provision'. Previously, up to 11,497,622 shares were registered under a prior Form S-8 filed on December 1, 2023. The contents of the prior registration statement are incorporated by reference into this new registration statement, which includes only new information not previously disclosed.
Conduit Pharmicals Inc.已於2024年1月10日向美國證券交易委員會（SEC）提交了S-8表格的註冊聲明。該文件登記了根據公司2023年股票激勵計劃可能發行的另外3,691,476股普通股。該計劃包括每年自動增加可供發行的股票數量，這將從2024年1月1日起在每個財政年度的第一天進行，並將持續到2033年1月。增幅是上一財年末已發行普通股的5％或董事會或其薪酬委員會確定的較小數字，以較低者爲準。新註冊的股票是這個 “計劃常青條款” 的結果。此前，根據先前於2023年12月1日提交的S-8表格，註冊了多達11,497,622股股票。先前註冊聲明的內容以引用方式納入本新的註冊聲明，其中僅包括以前未披露的新信息。
Conduit Pharmicals Inc.已於2024年1月10日向美國證券交易委員會（SEC）提交了S-8表格的註冊聲明。該文件登記了根據公司2023年股票激勵計劃可能發行的另外3,691,476股普通股。該計劃包括每年自動增加可供發行的股票數量，這將從2024年1月1日起在每個財政年度的第一天進行，並將持續到2033年1月。增幅是上一財年末已發行普通股的5％或董事會或其薪酬委員會確定的較小數字，以較低者爲準。新註冊的股票是這個 “計劃常青條款” 的結果。此前，根據先前於2023年12月1日提交的S-8表格，註冊了多達11,497,622股股票。先前註冊聲明的內容以引用方式納入本新的註冊聲明，其中僅包括以前未披露的新信息。
有用
沒用